Adrenergic activity and aldosterone regulation: no evidence for an alpha-1 adrenoceptor-mediated influence in normal subjects

Hormonal and humeral considerations in hypertensive disease

This article has discussed the classic hormonal causes of hypertension. Pheochromocytoma and hyperaldosteronism have been discussed, and a clinical approach to evaluation of patients for these problems has been presented. Other humeral factors that influence volume pressure homeostasis have been discussed. It is likely that pharmacologic agents affecting these other factors will become available to patients with hypertension in the future.

Primary aldosteronism: diagnosis and treatment

The syndrome of primary aldosteronism produces few signs or symptoms. The diagnosis should be suspected when either spontaneous hypokalemia or easily provoked hypokalemia is found in a patient with hypertension. Hypokalemia in association with inappropriate kaliuresis, low plasma renin activity, and a high plasma aldosterone concentration/plasma renin activity ratio are the findings on initial screening tests that should suggest primary aldosteronism. The diagnosis must be confirmed by demonstrating nonsuppressible aldosterone excretion in conjunction with normal cortisol excretion. The choice of therapy is based on distinguishing unilateral from bilateral adrenal disease. With a unilateral adrenal adenoma, surgical removal reverses the hypokalemia and frequently cures the hypertension. In most patients with bilateral adrenal hyperplasia who are treated surgically, however, hypertension persists; thus, the initial treatment in these patients should be pharmacologic.

Yohimbine and aldosterone responsiveness to angiotensin II or corticotrophin in normal subjects

In normal man the sympathetic nervous system exerts an inhibitory influence on aldosterone responsiveness to angiotensin II. The possible role of alpha-2 adrenoceptors was assessed by studying the changes of plasma aldosterone during an angiotensin II infusion at the dose of 1, 2, 5 and 10 ng/kg. min or after corticotrophin infusion, 0.25 mg, in 8 normal subjects before and after treatment with the selective alpha-2 adrenoceptor antagonist, yohimbine, at a maximal dosage of 60 mg daily. Yohimbine did not modify blood pressure, body weight, the supine levels of angiotensin II, renin and aldosterone, the pressor response to angiotensin II and the correlation relating plasma aldosterone to plasma angiotensin II obtained during infusion studies. These findings suggest that the inhibitory influence of the sympathetic nervous system on aldosterone responsiveness to angiotensin II.